Guidelines for therapeutic interchange - 2004

Pharmacotherapy

Volumn 25, Issue 11 I, 2005, Pages 1666-1680

  Gray, Thomas ^a   Bertch, Karen ^b   Galt, Kimberly ^b   Gonyeau, Michael ^b   Karpiuk, Emilie ^b   Oyen, Lance ^b   Sudekum, Mary Jane ^b   Vermeulen, Lee C ^b  

^a American Coll of Clinical Pharmacy   (United States)

^b NONE

Author keywords

ACCP; American College of Clinical Pharmacy; Cost effective therapy; Drug policies; Drug procedures; Guidelines; Patient care; Pharmacy and therapeutics committee; Position statement; Therapeutic interchange

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANALGESIC AGENT; ANTACID AGENT; ANTIINFECTIVE AGENT; ANTITUSSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; DECONGESTIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; GASTROINTESTINAL AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; MACROLIDE; NEUROMUSCULAR BLOCKING AGENT; NITRATE; ORAL CONTRACEPTIVE AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN 3 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDICATION; DRUG INFORMATION; DRUG SURVEILLANCE PROGRAM; DRUG USE; HEALTH CARE PERSONNEL; HOSPITAL PHARMACY; HUMAN; MEDICAL DECISION MAKING; PATIENT CARE; POLICY; PRACTICE GUIDELINE; REVIEW;

COST-BENEFIT ANALYSIS; DRUG COSTS; FORMULARIES, HOSPITAL; GUIDELINES; HUMANS; PHARMACY AND THERAPEUTICS COMMITTEE; PHARMACY SERVICE, HOSPITAL; THERAPEUTIC EQUIVALENCY;

EID: 27644493751     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.11.1666     Document Type: Review

References (63)

1. American College of Clinical Pharmacy. ACCP position statement: guidelines for therapeutic interchange. Pharmacotherapy 1993;13:252-6.
2. American Society of Hospital Pharmacists. ASHP guidelines on formulary system management. Am J Hosp Pharm 1992;49:648-52.
3. Carroll NV. Formularies and therapeutic interchange: the health care setting makes a difference. Am J Health-Syst Pharm 1999;56:467-72.
4. Nelson KM. Improving ambulatory care through therapeutic interchange [editorial]. Am J Health-Syst Pharm 1999;56:1307.
5. Carroll NV. Therapeutic interchange in community pharmacies in Virginia. Am J Health-Syst Pharm 2000;57:882-6.
6. Fish L, Edelman-Lewis B. The impact of a therapeutic interchange program in a managed care organization. J Manage Care Pharm 1999;5:438-41.
7. Sodorff MM, Gait KA, Gait MA. Pharmacists' perceptions of a therapeutic interchange program. Am J Health-Syst Pharm 2000;57:999-1000.
8. Gait KA, Sodorff MM, Gait MA, Lambrecht JE. Impact of a hospital-based therapeutic interchange program on patients' medication access and use after discharge. P&T 2001;26:151-3, 157-61.
9. Sodorff MM, Gait KA, Gait MA, Turner PD, Lambrecht JE. Patient perceptions of a proton pump inhibitor therapeutic interchange program across the continuum of care. Pharmacotherapy 2002;22:500-12.
10. Nelson WW, Vermeulen LC, Geurkink EA, Ehlert DA, Reichelderfer M. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole. Arch Intern Med 2000;160:2491-6.
11. Bollinger KA, Vermeulen LC, Davis SN, Geurkink EA. Use of outcomes research to support medication use policy: comparative effectiveness of low molecular weight heparins following therapeutic interchange. Am J Health-Syst Pharm 2000;57:368-72.
12. 2-antagonist. Hosp Pharm 2000;35:728-31.
13. Friedman MA, Swerlein A, Hammond R, Meyer J. Impact of a hospital-based computerized pharmacy order entry documentation of therapeutic interchange on the continuity of patients' medication regimen at discharge [abstr]. ASHP Midyear Clinical Meeting 2001;36:NTP-11.
14. Vermeulen LC, Beis S, Cano S. Improving the medication use process using outcomes research. Am J Health-Syst Pharm 2000;57:2277-82.
15. Teich JM, Merchia PR, Schmiz JL, et al. Effects of computerized physician order entry on prescribing practices. Arch Intern Med 2000;160:2741-7.
16. Bailey TC, McMullin ST. Using information systems technology to improve antibiotic prescribing. Crit Care Med 2001;29:N87-91.
17. Glemaud I. Use of a physician order entry system to identify opportunities for intravenous to oral levofloxacin conversion. Am J Health-Syst Pharm 2000;57:S14-16.
18. Monane M, Dipika MM, Nagle BA, et al. Improving prescribing patterns for the elderly through an online drug utilization review intervention. JAMA 1998;280:1249-52.
19. Hunt DL, Haynes RB, Hanna SE, et al. Effects of computer-based clinical decision support systems on physician performance and patient outcomes. JAMA 1998;280:1339-46.
20. American Medical Association. H-285.982 ethical issues in managed care. Available from http://www.ama-assn.org/apps/ pf_onlinepf_online?f_n= resultLink&doc=policyfiles/HOD/H28 5.982HTM. Accessed January 30, 2003.
21. Heiner CR. Communicating about therapeutic interchange. Am J Health-Syst Pharm 1996;53:2568-70.
22. Schachtner JM, Guharoy R, Medicis JJ, Newman N, Speizer R. Prevalence and cost savings of therapeutic interchange among U.S. hospitals. Am J Health-Syst Pharm 2002;59:529-33.
23. Goldwater SH, Milkovich G, Morrison AJ, Lindgren B. Comparison of therapeutic interchange with standard educational tools for influencing fluoroquinolone prescribing. Am J Health-Syst Pharm 2001;58:1740-5.
24. Shane R. Strategic management of pharmaceutical expenses. Am J Health-Syst Pharm 2001;58:406-9.
25. Halley HJ. Approaches to drug therapy, formulary, and pathway management in a large community hospital. Am J Health-Syst Pharm 2000;57(suppl 3):S17-21.
26. Hekster YA. Target drug programs and medication use evaluation. Pharmacotherapy 2000;20(10 pt 2):S322-6.
27. Scroccaro G. Formulary management. Pharmacotherapy 2000;20(10 pt 2):S317-21.
28. Shah ND, Hoffman JM, Vermeulen LC, Hunkler RJ, Hontz KM. Projecting future drug expenditures-2003. Am J Health-Syst Pharm 2003;60:137-49.
29. Swartwood DE. Ethics and managed care formularies [editorial]. Am J Health-Syst Pharm 2000;57:851.
30. Jonsen A. Fortresses and formularies: drugs, ethics, and managed care. Am J Health-Syst Pharm 2000;57:853-6.
31. Skledar SJ, Hess MM. Implementation of a drug-use and disease-state management program. Am J Health-Syst Pharm 2000;57(suppl 4):S23-9.
32. Liang FZ, Greenberg RB, Hoga GF. Legal issues associated with product selection when there are two or more recognized drug therapies. Am J Hosp Pharm 1988;45:2372-5.
33. Brushwood DB. Legal issues surrounding therapeutic interchange in institutional settings: an update. Formulary 2001;36:796-804.
34. Thompson v Nason Hospital, 591 A2d 703 (Pa 1991).
35. Philadelphia County Reporter. Lexis 16. June 3, 1997.
36. American Medical Association, Council on Ethical and Judicial Affairs. Managed care cost containment involving prescription drugs. Food Drug Law J 1998;53:25-34.
37. Fla Stat 465.019.
38. Shapiro SA. Limiting physician freedom to prescribe a drug any purpose: the need for FDA regulation. Northwestern Univ Law Rev 1979;73:801-73.
39. Wilsker JA. One-half phen in the morning, one fen before dinner: a proposal for FDA regulation of off-label uses of drugs. J Law Policy 1998;6:795-851.
40. Blum RS. Legal considerations in off-label medication prescribing. Arch Intern Med 2002;162:1777-9.
41. Hutt PB, Merrill RA. Food and drug law. University Casebook Series 1991:616-31.
42. Kessler DA. Regulating the prescribing of human drugs for nonapproved uses under the Food, Drug, and Cosmetic Act. Harvard J Legis 1978;15:693-760.
43. Joint Commission on Accreditation of Healthcare Organization. Joint Commission on Accreditation of Healthcare Organizations standards. Available from www.jcaho.org. Accessed February 9, 2003.
44. American Society of Health-System Pharmacists. Principles of a sound drug formulary system. Available from http://www.ashp.com/search/searchaction/cfm? cfid=1364507&. CFToken=8430746. Accessed June 9, 2004.
45. California Society of Health-System Pharmacists. CSHP catalog of professional policy. Available from http://www.cshp. org/. Accessed January 2, 2003.
46. Virginia Society of Health-System Pharmacists. Position statement: therapeutic interchange. Available from http://www.vshp.org/ppthrint.htm. Accessed January 2, 2002.
47. Academy of Managed Care Pharmacy. Position statement on therapeutic interchange. Available from http://www.amcp.org/ professional_res/position/007. asp. Accessed January 2, 2003.
48. American Society of Consultant Pharmacists. Guidelines for implementing therapeutic interchange in long-term care. Available from http://www.ascp.com/ public/pr/guidelines/ therapeutic.shtml. Accessed January 2, 2003.
49. American Pharmaceutical Association. Position of the American Pharmaceutical Association on the issue of therapeutic interchange. Washington, DC: American Pharmaceutical Association, 1987.
50. American Association of Colleges of Pharmacy. Center for the Advancement of Pharmaceutical Education Advisory Panel. Educational outcomes. Available from http://www.aacp.org/ Docs/MainNavigation/Resources/3933_edoutcom.doc?DocType ID=4&TrackID=www.aacp.org/search/search.asp. Accessed February 5, 2003.
51. International Pharmaceutical Federation. FIP statement of principle: pharmacist's authority in product selection. Therapeutic interchange and generic substitution. Available from http://www.fip.org/pdfprodsel.pdf. Accessed February 19, 2003.
52. Anonymous. Technician status, therapeutic interchange are subjects of resolutions by National Association of Boards of Pharmacy. Am J Hosp Pharm 1993;50:1535, 1538.
53. American Medical Association. H-125.991 Drug formularies and therapeutic interchange. Available from http://www.ama-assn.org/apps/pf_online? f_n=resultLink&doc=policyfiles/HOD/ H125.991.HTM. Accessed January 2, 2003.
54. American College of Physicians-American Society of Internal Medicine. Pharmacist scope of practice. Ann Intern Med 2002;136:79-85.
55. American Psychiatric Association. Pharmacy benefit management/pharmacy benefit managers (PBMs): position statement. Available from http://www.psych. org/archives/ 200204.pdf. Accessed January 8, 2003.
56. American Heart Association. Drugs, therapeutic interchange and generic. Available from http://www.americanheart.org/ presenter.jhtml?identifier=4526. Accessed January 8, 2003.
57. Sabatini S, Ferguson RM, Helderman JH, Hull AR, Kirkpatrick BS, Barr WH. Drug substitution on transplantation: a National Kidney Foundation white paper. Am J Kidney Dis 1999;33:389-97.
58. Generic Pharmaceutical Industry Association. Policy on therapeutic interchange. New York: Generic Pharmaceutical Industry Association, 1992.
59. Pharmaceutical Manufacturers Association. Policy statement concerning drug selection. Washington, DC: Pharmaceutical Manufacturers Association, 1991:1-6.
60. Santell JP. ASHP national survey of hospital-based pharmaceutical services-1994. Am J Health-Syst Pharm 1995;52:1179-98.
61. Reeder CE, Dickson M, Kozma CM, Santell JP. ASHP national survey of pharmacy practice in acute care settings-1996. Am J Health-Syst Pharm 1996;54:653-69.
62. Eurich D, Poulin S, Semchuk W, Taylor J. Therapeutic interchange in Canadian hospitals: a national survey. Can J Hosp Pharm 2001;54:28-34.
63. Carroll NV. How effectively do managed care organizations influence prescribing and dispensing decisions? Am J Manage Care 2002;8:1041-54.